Results 21 to 30 of about 4,730,641 (404)

Bioinformatics exploration of potential common therapeutic targets for systemic and pulmonary arterial hypertension-induced myocardial hypertrophy

Acta Biochimica et Biophysica Sinica, 2023
Systemic and pulmonary arterial hypertension (PAH) can induce left and right ventricular hypertrophy, respectively, but common therapeutic targets for both left and right hypertrophy are limited.
Chen Lu, Li Mingjue, Shen Mengjia, Zhu Yingqi, Chen Kaitong, Huang Xiaoxia, Zheng Cankun, Wang Qiancheng, Lin Hairuo, Liao Wangjun, Bin Jianping, Ma Siyuan, Liao Yulin   +12 more
doaj   +1 more source

Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation

Scientific Reports, 2022
Primary ventricular fibrillation (PVF) is a life-threatening complication of ST-segment elevation myocardial infarction (STEMI). It is unclear what roles viral infection and/or systemic inflammation may play as underlying triggers of PVF, as a second hit
Teresa Oliveras, Elena Revuelta-López, Cosme García-García, Adriana Cserkóová, Ferran Rueda, Carlos Labata, Marc Ferrer, Santiago Montero, Nabil El-Ouaddi, Maria José Martínez, Santiago Roura, Carolina Gálvez-Montón, Antoni Bayes-Genis   +12 more
doaj   +1 more source

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

New England Journal of Medicine, 2020
BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.
J. Teerlink, R. Diaz, G. Felker, J. McMurray, M. Metra, S. Solomon, K. Adams, I. Anand, Alexandra Arias-Mendoza, T. Biering-Sørensen, M. Böhm, D. Bonderman, J. Cleland, R. Corbalán, M. Crespo-Leiro, U. Dahlström, L. E. Echeverría, J. Fang, G. Filippatos, C. Fonseca, E. Goncalvesova, A. Goudev, J. Howlett, D. Lanfear, Jing Li, M. Lund, P. Macdonald, V. Mareev, S. Momomura, E. O’Meara, A. Parkhomenko, P. Ponikowski, F. Ramires, P. Serpytis, K. Sliwa, J. Špinar, T. Suter, J. Tomcsányi, H. Vandekerckhove, D. Vinereanu, A. Voors, M. Yılmaz, F. Zannad, L. Sharpsten, J. Legg, C. Varin, Narimon Honarpour, Siddique A Abbasi, F. Malik, C. Kurtz   +49 more
semanticscholar   +1 more source

Association between the Length of Hospital Stay and 30-Day Outcomes in Patients Admitted with Acute Decompensated Heart Failure

Emergency Medicine International, 2023
Background and Aim. Regarding patients admitted with acute decompensated heart failure (ADHF), there are inconsistent reports surrounding the association between length of stay (LOS) and mortality or rehospitalization following discharge.
Melika Namvar, Mohammad Fakhrolmobasheri, Sadegh Mazaheri-Tehrani, Maryam Heidarpour, Maryam Emamimeybodi, Davood Shafie   +5 more
doaj   +1 more source

Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial

Cardiology Research and Practice, 2022
Aim. This study aimed to explore if supplementary lycopene tablets may help heart failure (HF) patients improve their lipid profile, BP, and the flow-mediated dilation (FMD) index for endothelial function. Methods.
Bahareh Karimian, Azam Soleimani, Ghasem Mohammadsharifi, Kiyan Heshmat-Ghahdarijani, Laila Rejali, Davood Shafie, Atefeh Amerizadeh, Masoumeh Sadeghi   +7 more
doaj   +1 more source

Biomarker profiles of acute heart failure patients with a mid-range ejection fraction [PDF]

, 2017
OBJECTIVES: In this study, the authors used biomarker profiles to characterize differences between patients with acute heart failure with a midrange ejection fraction (HFmrEF) and compare them with patients with a reduced (heart failure with a ...
Bloomfield, Daniel M, Cleland, John G.F., Cotter, Gad, Davison, Beth, Dittrich, Howard C, Givertz, Michael M, Hillege, Hans L, Khan, Mohsin A F, Mentz, Robert J, Metra, Marco, O'Connor, Christopher M, Ponikowski, Piotr, Teerlink, John R, Tromp, Jasper, van der Meer, Peter, Van Veldhuisen, Dirk J, Voors, Adriaan A.   +16 more
core   +4 more sources

A review of the molecular mechanisms underlying the development and progression of cardiac remodeling [PDF]

, 2017
Pathological molecular mechanisms involved in myocardial remodeling contribute to alter the existing structure of the heart, leading to cardiac dysfunction.
Angelini, Francesco, Bordin, Antonella, Carrizzo, Albino, Chimenti, Isotta, DE FALCO, Elena, Forte, Maurizio, Frati, Giacomo, Nocella, Cristina, Pagano, Francesca, Palmerio, Silvia, Schiavon, Sonia, Schirone, Leonardo, Sciarretta, Sebastiano, Valenti, Valentina, Vecchione, Carmine, Yee, Derek   +15 more
core   +3 more sources

Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure [PDF]

, 2019
Heart failure is a leading cause of mortality, yet our understanding of the genetic interactions underlying this disease remains incomplete. Here, we harvest 1352 healthy and failing human hearts directly from transplant center operating rooms, and ...
Ashley, Euan A., Bernstein, Daniel, Brandimarto, Jeff, Cappola, Thomas, Chang, Alex C., Chin, Elizabeth T., Connolly, Andrew, Cordero, Pablo, Depaoli-Roach, Anna A., Dewey, Frederick, Erbilgin, Ayca, Glazer, Nicole, Gloudemans, Michael J., Hakonarson, Hakon, Hannenhalli, Sridhar, Huang, Yong, Li, Hongzhe, Li, Mingyao, Lusis, Aldons J., Malloy, Christine, Margulies, Kenneth B., Montgomery, Stephen B., Moravec, Christine S., Morley, Michael, Parikh, Victoria N., Pavlovic, Aleksandra, Ritter, Scott, Shang, Ching, Skreen, Jamie, Smith, Kevin S., Tang, W. H. Wilson, Waggott, Daryl, Wheeler, Matthew T., Zaleta, Kathia, Zhao, Mingming   +34 more
core   +2 more sources

The relation between cardiac 123I-mIBG scintigraphy and functional response 1 year after CRT implantation [PDF]

, 2020
Cardiac resynchronization therapy (CRT) is a disease-modifying therapy in patients with chronic heart failure (CHF). Current guidelines ascribe CRT eligibility on three parameters only: left ventricular ejection fraction (LVEF), QRS duration, and New ...
de Groot, J R, De Vincentis, G, Frantellizzi, V, Gheysens, O, Nakajima, K, Poel, E, Verberne, H J, Verschure, D O   +7 more
core   +1 more source

Myocardial recovery evaluation from ventricular assist device in patients with dilated cardiomyopathy

ESC Heart Failure, 2022
Aims The removal of left ventricular assist device (LVAD) after myocardial recovery can provide survival benefits with freedom from LVAD‐associated complications.
Takayuki Gyoten, Eisuke Amiya, Osamu Kinoshita, Masaki Tsuji, Mitsutoshi Kimura, Masaru Hatano, Minoru Ono   +6 more
doaj   +1 more source